[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.176.252. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
September 27, 2006

Clinical Trials in Hypertension

JAMA. 2006;296(12):1463-1465. doi:10.1001/jama.296.12.1463

To the Editor: In their Commentary, Dr Psaty and colleagues1 stated that recent meta-analyses by Carlberg et al2 and Lindholm et al3 confirm their own previous meta-analysis.4 However, their conclusions in that review were that “the available scientific evidence provides strong support for the current national guidelines, which recommend diuretics and β-blockers as first-line agents . . . .” In contrast, Carlberg et al2 concluded that “our results cast doubts on atenolol as a suitable drug for hypertensive patients.” Lindholm et al3 concluded that “we believe that β-blockers should not remain first choice in the treatment of primary hypertension . . . .”

First Page Preview View Large
First page PDF preview
First page PDF preview
×